Emotion Regulation-based Internet-delivered Cognitive Behavioural Therapy for Premenstrual Dysphoric Disorder

Launched by UPPSALA UNIVERSITY · Jul 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new online therapy program designed to help women with Premenstrual Dysphoric Disorder (PMDD), a condition that causes severe emotional and physical symptoms before their period starts. The goal is to see if this internet-delivered Cognitive Behavioral Therapy (ICBT) can effectively teach women skills to manage their emotions and improve their relationships, potentially offering a helpful alternative to traditional medications.

To participate in the trial, women must have a confirmed diagnosis of PMDD and a regular menstrual cycle. They should also be able to read and understand Swedish and have access to the internet. Participants will complete the online therapy program and share their experiences. It's important to note that women who are pregnant, breastfeeding, or have certain medical or mental health conditions may not be eligible for this study. This research aims to provide more effective treatment options for those struggling with PMDD, as current medications don’t work for everyone.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. PMDD diagnosis according to DSM-5
• • 2. Menstrual cycle length between 23-34 days, i.e., 5-8 cycles in the last six months
• • 3. Sufficient proficiency in Swedish to comprehend the treatment materials
• • 4. Access to computer/tablet/mobile phone with internet connection
• Exclusion Criteria:
• • 1. Breastfeeding or pregnancy during the previous three months
• • 2. Initiation of or change in treatment with antidepressants, benzodiazepines, contraceptives, or hormones during the last three months
• • 3. Current or history of a gynaecological disease (e.g., endometriosis, polycystic ovary syndrome) that may confound the results
• • 4. Ongoing or previous psychological treatment for premenstrual disorders
• • 5. Severe mental disorders that may interfere with the person's ability to complete the treatment or complicate the interpretation of results, e.g., psychosis, bipolar disorder, severe eating disorder, or severe depression
• • 6. Elevated suicide risk (e.g., recurrent active suicidal ideation, current suicide plans, previous suicide attempts).